Pharmacogenomics Market Size, Share, Global Forecast 2032

Pharmacogenomics Market

Pharmacogenomics Market By Technology (Microarray, Polymerase Chain Reaction, Sequencing, Electrophoresis, Mass Spectrometry, and Others), By Application (Infectious Diseases, Oncology, Neurological Diseases, Cardiovascular Diseases, Pain Management, Psychiatry, and Others), By End-User (Research Institutions, Hospitals and Clinics, and Academic Institutes), and By Region: Global Industry Perspective, Comprehensive Analysis and Forecast, 2024 - 2032

Category: Healthcare Report Format : PDF Pages: 210 Report Code: ZMR-5104 Published Date: Jun-2024 Status : Published
Market Size in 2023 Market Forecast in 2032 CAGR (in %) Base Year
USD 3.45 Billion USD 8.36 Billion 10.33% 2023

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Pharmacogenomics, 2024-2032 (USD Billion)
    • 2.2. Pharmacogenomics: Snapshot
  • Chapter 3. Pharmacogenomics - Industry Analysis
    • 3.1. Pharmacogenomics: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Increasing implementation of pharmacogenomics procedure
      • 3.2.2. Growing geriatric population
    • 3.3. Restraints
      • 3.3.1. High cost of diagnosis
      • 3.3.2. Lack of skilled professionals
    • 3.4. Opportunity
      • 3.4.1. Technological advancements in the field of pharmacogenomics
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis By Technology
      • 3.6.2. Market attractiveness analysis By Application
      • 3.6.3. Market attractiveness analysis By End User
      • 3.6.4. Market attractiveness analysis by Region
  • Chapter 4. Pharmacogenomics- Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Pharmacogenomics: company market share, 2024
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Technology launches
      • 4.2.3. Agreements, partnerships, collaborations and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Pharmacogenomics -Technology Analysis
    • 5.1. Global Pharmacogenomics overview: By Technology type
      • 5.1.1. Global Pharmacogenomics share, By Technology,2024 and 2032
    • 5.2. Microarray
      • 5.2.1. Global Pharmacogenomics by Microarray, 2024-2032 (USD Billion)
    • 5.3. Polymerase Chain Reaction
      • 5.3.1. Global Pharmacogenomics by Polymerase Chain Reaction, 2024-2032 (USD Billion)
    • 5.4. Sequencing
      • 5.4.1. Global Pharmacogenomics by Sequencing, 2024-2032 (USD Billion)
    • 5.5. Electrophoresis
      • 5.5.1. Global Pharmacogenomics by Electrophoresis, 2024-2032 (USD Billion)
    • 5.6. Mass Spectrometry
      • 5.6.1. Global Pharmacogenomics by Mass Spectrometry, 2024-2032 (USD Billion)
    • 5.7. Others
      • 5.7.1. Global Pharmacogenomics by Others, 2024-2032 (USD Billion)
  • Chapter 6. Global Pharmacogenomics -Application Analysis
    • 6.1. Global Pharmacogenomics overview: By Application
      • 6.1.1. Global Pharmacogenomics share, By Application, 2024 and 2032
    • 6.2. Infectious Diseases
      • 6.2.1. Global Pharmacogenomics By Infectious Diseases, 2024-2032 (USD Billion)
    • 6.3. Oncology
      • 6.3.1. Global Pharmacogenomics By Oncology, 2024-2032 (USD Billion)
    • 6.4. Neurological Diseases
      • 6.4.1. Global Pharmacogenomics By Neurological Diseases, 2024-2032 (USD Billion)
    • 6.5. Cardiovascular Diseases
      • 6.5.1. Global Pharmacogenomics By Cardiovascular Diseases, 2024-2032 (USD Billion)
    • 6.6. Infectious Disease
      • 6.6.1. Global Pharmacogenomics By Infectious Disease, 2024-2032 (USD Billion)
    • 6.7. Pain Management
      • 6.7.1. Global Pharmacogenomics by Pain Management, 2024-2032 (USD Billion)
    • 6.8. Psychiatry
      • 6.8.1. Global Pharmacogenomics by Psychiatry, 2024-2032 (USD Billion)
    • 6.9. Others
      • 6.9.1. Global Pharmacogenomics by Others, 2024-2032 (USD Billion)
  • Chapter 7. Global Pharmacogenomics -End User Analysis
    • 7.1. Global Pharmacogenomics overview: By End User
      • 7.1.1. Global Pharmacogenomics share, By End User, 2024 and 2032
    • 7.2. Research Institutions
      • 7.2.1. Global Pharmacogenomics by Research Institutions, 2024-2032 (USD Billion)
    • 7.3. Hospitals and Clinics
      • 7.3.1. Global Pharmacogenomics by Hospitals and Clinics, 2024-2032 (USD Billion)
    • 7.4. Academic Institutes
      • 7.4.1. Global Pharmacogenomics by Academic Institutes, 2024-2032 (USD Billion)
  • Chapter 8. Global Pharmacogenomics - Regional Analysis
    • 8.1. Global Pharmacogenomics overview: by Region
      • 8.1.1. Global Pharmacogenomics share, by Region, 2024 and 2032
    • 8.2. North America
      • 8.2.1. North America Pharmacogenomics, 2024-2032 (USD Billion)
      • 8.2.2. North America Pharmacogenomics revenue, By Technology,2024-2032 (USD Billion)
      • 8.2.3. North America Pharmacogenomics revenue, By Application, 2024-2032 (USD Billion)
      • 8.2.4. North America Pharmacogenomics revenue, By End User, 2024-2032 (USD Billion)
      • 8.2.5. The U.S.
        • 8.2.5.1. The U.S. Pharmacogenomics revenue, By Technology,2024-2032 (USD Billion)
        • 8.2.5.2. The U.S. Pharmacogenomics revenue, By Application, 2024-2032 (USD Billion)
        • 8.2.5.3. The U.S. Pharmacogenomics revenue, By End User, 2024-2032 (USD Billion)
      • 8.2.6. Rest of North America
        • 8.2.6.1. Rest of North America Pharmacogenomics revenue, By Technology,2024-2032 (USD Billion)
        • 8.2.6.2. Rest of North America Pharmacogenomics revenue, By Application, 2024-2032 (USD Billion)
        • 8.2.6.3. Rest of North America Pharmacogenomics revenue, By End User, 2024-2032 (USD Billion)
    • 8.3. Europe
      • 8.3.1. Europe Pharmacogenomics, 2024-2032 (USD Billion)
      • 8.3.2. Europe Pharmacogenomics revenue, By Technology,2024-2032 (USD Billion)
      • 8.3.3. Europe Pharmacogenomics revenue, By Application, 2024-2032 (USD Billion)
      • 8.3.4. Europe Pharmacogenomics revenue, By End User, 2024-2032 (USD Billion)
      • 8.3.5. UK
        • 8.3.5.1. U.K. Pharmacogenomics revenue, By Technology,2024-2032 (USD Billion)
        • 8.3.5.2. U.K. Pharmacogenomics revenue, By Application, 2024-2032 (USD Billion)
        • 8.3.5.3. U.K. Pharmacogenomics revenue, By End User, 2024-2032 (USD Billion)
      • 8.3.6. France
        • 8.3.6.1. France Pharmacogenomics revenue, By Technology,2024-2032 (USD Billion)
        • 8.3.6.2. France Pharmacogenomics revenue, By Application, 2024-2032 (USD Billion)
        • 8.3.6.3. France Pharmacogenomics revenue, By End User, 2024-2032 (USD Billion)
      • 8.3.7. Germany
        • 8.3.7.1. Germany Pharmacogenomics revenue, By Technology,2024-2032 (USD Billion)
        • 8.3.7.2. Germany Pharmacogenomics revenue, By Application, 2024-2032 (USD Billion)
        • 8.3.7.3. Germany Pharmacogenomics revenue, By End User, 2024-2032 (USD Billion)
      • 8.3.8. Rest of Europe
        • 8.3.8.1. Rest of Europe Pharmacogenomics revenue, By Technology,2024-2032 (USD Billion)
        • 8.3.8.2. Rest of Europe Pharmacogenomics revenue, By Application, 2024-2032 (USD Billion)
        • 8.3.8.3. Rest of Europe Pharmacogenomics revenue, By End User, 2024-2032 (USD Billion)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific Pharmacogenomics, 2024-2032 (USD Billion)
      • 8.4.2. Asia Pacific Pharmacogenomics revenue, By Technology,2024-2032 (USD Billion)
      • 8.4.3. Asia Pacific Pharmacogenomics revenue, By Application, 2024-2032 (USD Billion)
      • 8.4.4. Asia Pacific Pharmacogenomics revenue, By End User, 2024-2032 (USD Billion)
      • 8.4.5. China
        • 8.4.5.1. China Pharmacogenomics revenue, By Technology,2024-2032 (USD Billion)
        • 8.4.5.2. China Pharmacogenomics revenue, By Application, 2024-2032 (USD Billion)
        • 8.4.5.3. China Pharmacogenomics revenue, By End User, 2024-2032 (USD Billion)
      • 8.4.6. Japan
        • 8.4.6.1. Japan Pharmacogenomics revenue, By Technology,2024-2032 (USD Billion)
        • 8.4.6.2. Japan Pharmacogenomics revenue, By Application, 2024-2032 (USD Billion)
        • 8.4.6.3. Japan Pharmacogenomics revenue, By End User, 2024-2032 (USD Billion)
      • 8.4.7. India
        • 8.4.7.1. India Pharmacogenomics revenue, By Technology,2024-2032 (USD Billion)
        • 8.4.7.2. India Pharmacogenomics revenue, By Application, 2024-2032 (USD Billion)
        • 8.4.7.3. India Pharmacogenomics revenue, By End User, 2024-2032 (USD Billion)
      • 8.4.8. Rest of Asia Pacific
        • 8.4.8.1. Rest of Asia Pacific Pharmacogenomics revenue, By Technology,2024-2032 (USD Billion)
        • 8.4.8.2. Rest of Asia Pacific Pharmacogenomics revenue, By Application, 2024-2032 (USD Billion)
        • 8.4.8.3. Rest of Asia Pacific Pharmacogenomics revenue, By End User, 2024-2032 (USD Billion)
    • 8.5. Latin America
      • 8.5.1. Latin America Pharmacogenomics, 2024-2032 (USD Billion)
      • 8.5.2. Latin America Pharmacogenomics revenue, By Technology,2024-2032 (USD Billion)
      • 8.5.3. Latin America Pharmacogenomics revenue, By Application, 2024-2032 (USD Billion)
      • 8.5.4. Latin America Pharmacogenomics revenue, By End User, 2024-2032 (USD Billion)
      • 8.5.5. Brazil
        • 8.5.5.1. Brazil Pharmacogenomics revenue, By Technology,2024-2032 (USD Billion)
        • 8.5.5.2. Brazil Pharmacogenomics revenue, By Application, 2024-2032 (USD Billion)
        • 8.5.5.3. Brazil Pharmacogenomics revenue, By End User, 2024-2032 (USD Billion)
      • 8.5.6. Rest of Latin America
        • 8.5.6.1. Rest of Latin America Pharmacogenomics revenue, By Technology,2024-2032 (USD Billion)
        • 8.5.6.2. Rest of Latin America Pharmacogenomics revenue, By Application, 2024-2032 (USD Billion)
        • 8.5.6.3. Rest of Latin America Pharmacogenomics revenue, By End User, 2024-2032 (USD Billion)
    • 8.6. The Middle East and Africa
      • 8.6.1. The Middle East and Africa Pharmacogenomics, 2024-2032 (USD Billion)
      • 8.6.2. The Middle East and Africa Pharmacogenomics revenue, By Technology,2024-2032 (USD Billion)
      • 8.6.3. The Middle East and Africa Pharmacogenomics revenue, By Application, 2024-2032 (USD Billion)
      • 8.6.4. The Middle East and Africa Pharmacogenomics revenue, By End User, 2024-2032 (USD Billion)
  • Chapter 9. Company Profiles
    • 9.1. Dynamic DNA Laboratories
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Technology Portfolio
      • 9.1.4. Business Strategy
      • 9.1.5. Recent Developments
    • 9.2. Abbott Laboratories
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Technology Portfolio
      • 9.2.4. Business Strategy
      • 9.2.5. Recent Developments
    • 9.3. Empire Genomics, LLC
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Technology Portfolio
      • 9.3.4. Business Strategy
      • 9.3.5. Recent Developments
    • 9.4. Illumina, Inc.
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Technology Portfolio
      • 9.4.4. Business Strategy
      • 9.4.5. Recent Developments
    • 9.5. F. Hoffmann-La Roche Ltd.
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Technology Portfolio
      • 9.5.4. Business Strategy
      • 9.5.5. Recent Development
    • 9.6. Myriad Genetics Inc.
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Technology Portfolio
      • 9.6.4. Business Strategy
      • 9.6.5. Recent Development
    • 9.7. OneOme LLC
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Technology Portfolio
      • 9.7.4. Business Strategy
      • 9.7.5. Recent Development
    • 9.8. Thermo Fisher Scientific, Inc.
      • 9.8.1. Overview
      • 9.8.2. Financials
      • 9.8.3. Technology Portfolio
      • 9.8.4. Business Strategy
      • 9.8.5. Recent Development
    • 9.9. OPKO Health, Inc.
      • 9.9.1. Overview
      • 9.9.2. Financials
      • 9.9.3. Technology Portfolio
      • 9.9.4. Business Strategy
      • 9.9.5. Recent Development

Table Of Figures

List of Figures

1. Market research process
2. Market research methodology
3. Global Pharmacogenomics, 2024–2032 (USD Billion)
4. Porter’s Five Forces Analysis
5. Global Pharmacogenomics attractiveness, By Technology type
6. Global Pharmacogenomics attractiveness, By Application
7. Global Pharmacogenomics attractiveness, By End User
8. Global Pharmacogenomics market share, By Technology, 2024 and 2032
9. Global Pharmacogenomics by Microarray, 2024–2032 (USD Billion)
10. Global Pharmacogenomics by Polymerase Chain Reaction,2024–2032 (USD Billion)
11. Global Pharmacogenomics by Sequencing,2024–2032 (USD Billion)
12. Global Pharmacogenomics by Electrophoresis,2024–2032 (USD Billion)
13. Global Pharmacogenomics by Mass Spectrometry,2024–2032 (USD Billion)
14. Global Pharmacogenomics by Others,2024–2032 (USD Billion)
15. Global Pharmacogenomics share, By Application, 2024 and 2032
16. Global Pharmacogenomics By Infectious Diseases, 2024–2032 (USD Billion)
17. Global Pharmacogenomics By Oncology, 2024–2032 (USD Billion)
18. Global Pharmacogenomics By Neurological Diseases, 2024–2032 (USD Billion)
19. Global Pharmacogenomics By Cardiovascular Diseases, 2024–2032 (USD Billion)
20. Global Pharmacogenomics By Infectious Disease, 2024–2032 (USD Billion)
21. Global Pharmacogenomics By Pain Management, 2024–2032 (USD Billion)
22. Global Pharmacogenomics By Psychiatry, 2024–2032 (USD Billion)
23. Global Pharmacogenomics By Others, 2024–2032 (USD Billion)
24. Global Pharmacogenomics share, By End User, 2024 and 2032
25. Global Pharmacogenomics by Research Institutions, 2024–2032 (USD Billion)
26. Global Pharmacogenomics by Hospitals and Clinics, 2024–2032 (USD Billion)
27. Global Pharmacogenomics by Academic Institutes, 2024–2032 (USD Billion)
28. Global Pharmacogenomics share, by Region, 2024and 2032
29. North America Pharmacogenomics, 2024–2032 (USD Billion)
30. Europe Pharmacogenomics, 2024–2032 (USD Billion)
31. Asia Pacific Pharmacogenomics, 2024–2032 (USD Billion)
32. Latin America Pharmacogenomics, 2024–2032 (USD Billion)
33. The Middle East and Africa Pharmacogenomics, 2024–2032 (USD Billion)


Table Of Tables

List of Tables

1. Global Pharmacogenomics: snapshot
2. Drivers of the Pharmacogenomics: impact analysis
3. Restraints of the Pharmacogenomics: impact analysis
4. North America Pharmacogenomics revenue, By Technology,2024–2032 (USD Billion)
5. North America Pharmacogenomics revenue, By Application, 2024–2032 (USD Billion)
6. North America Pharmacogenomics revenue, By End User, 2024–2032 (USD Billion)
7. The U.S. Pharmacogenomics revenue, By Technology,2024–2032 (USD Billion)
8. The U.S. Pharmacogenomics revenue, By Application, 2024–2032 (USD Billion)
9. The U.S. Pharmacogenomics revenue, By End User, 2024–2032 (USD Billion)
10. Rest of North America Pharmacogenomics revenue, By Technology,2024–2032 (USD Billion)
11. Rest of North America Pharmacogenomics revenue, By Application, 2024–2032 (USD Billion)
12. Rest of North America Pharmacogenomics revenue, By End User, 2024–2032 (USD Billion)
13. Europe Pharmacogenomics revenue, By Technology,2024–2032 (USD Billion)
14. Europe Pharmacogenomics revenue, By Application, 2024–2032 (USD Billion)
15. Europe Pharmacogenomics revenue, By End User, 2024–2032 (USD Billion)
16. U.K. Pharmacogenomics revenue, By Technology,2024–2032 (USD Billion)
17. U.K. Pharmacogenomics revenue, By Application, 2024–2032 (USD Billion)
18. U.K. Pharmacogenomics revenue, By End User, 2024–2032 (USD Billion)
19. France Pharmacogenomics revenue, By Technology,2024–2032 (USD Billion)
20. France Pharmacogenomics revenue, By Application, 2024–2032 (USD Billion)
21. France Pharmacogenomics revenue, By End User, 2024–2032 (USD Billion)
22. Germany Pharmacogenomics revenue, By Technology,2024–2032 (USD Billion)
23. Germany Pharmacogenomics revenue, By Application, 2024–2032 (USD Billion)
24. Germany Pharmacogenomics revenue, By End User, 2024–2032 (USD Billion)
25. Rest of Europe Pharmacogenomics revenue, By Technology,2024–2032 (USD Billion)
26. Rest of Europe Pharmacogenomics revenue, By Application, 2024–2032 (USD Billion)
27. Rest of Europe Pharmacogenomics revenue, By End User, 2024–2032 (USD Billion)
28. Asia Pacific Pharmacogenomics revenue, By Technology,2024–2032 (USD Billion)
29. Asia Pacific Pharmacogenomics revenue, By Application, 2024–2032 (USD Billion)
30. Asia Pacific Pharmacogenomics revenue, By End User, 2024–2032 (USD Billion)
31. China Pharmacogenomics revenue, By Technology,2024–2032 (USD Billion)
32. China Pharmacogenomics revenue, By Application, 2024–2032 (USD Billion)
33. China Pharmacogenomics revenue, By End User, 2024–2032 (USD Billion)
34. Japan Pharmacogenomics revenue, By Technology,2024–2032 (USD Billion)
35. Japan Pharmacogenomics revenue, By Application, 2024–2032 (USD Billion)
36. Japan Pharmacogenomics revenue, By End User, 2024–2032 (USD Billion)
37. India Pharmacogenomics revenue, By Technology,2024–2032 (USD Billion)
38. India Pharmacogenomics revenue, By Application, 2024–2032 (USD Billion)
39. India Pharmacogenomics revenue, By End User, 2024–2032 (USD Billion)
40. Rest of Asia Pacific Pharmacogenomics revenue, By Technology,2024–2032 (USD Billion)
41. Rest of Asia Pacific Pharmacogenomics revenue, By Application, 2024–2032 (USD Billion)
42. Rest of Asia Pacific Pharmacogenomics revenue, By End User, 2024–2032 (USD Billion)
43. Latin America Pharmacogenomics revenue, By Technology,2024–2032 (USD Billion)
44. Latin America Pharmacogenomics revenue, By Application, 2024–2032 (USD Billion)
45. Latin America Pharmacogenomics revenue, By End User, 2024–2032 (USD Billion)
46. Brazil Pharmacogenomics revenue, By Technology,2024–2032 (USD Billion)
47. Brazil Pharmacogenomics revenue, By Application, 2024–2032 (USD Billion)
48. Brazil Pharmacogenomics revenue, By End User, 2024–2032 (USD Billion)
49. Rest of Latin America Pharmacogenomics revenue, By Technology,2024–2032 (USD Billion)
50. Rest of Latin America Pharmacogenomics revenue, By Application, 2024–2032 (USD Billion)
51. Rest of Latin America Pharmacogenomics revenue, By End User, 2024–2032 (USD Billion)
52. The Middle East and Africa Pharmacogenomics revenue, By Technology,2024–2032 (USD Billion)
53. The Middle East and Africa Pharmacogenomics revenue, By Application, 2024–2032 (USD Billion)
54. The Middle East and Africa Pharmacogenomics revenue, By End User, 2024–2032 (USD Billion)
 

Methodology

FrequentlyAsked Questions

The field of study known as pharmacogenomics investigates how the genetic make-up of an individual (genomics) affects how they react to medications (pharmacology). It brings together the disciplines of pharmacology and genomics in an effort to gain a better understanding of the ways in which changes in a person's genetic makeup might influence both their susceptibility to certain diseases and their response to various drugs. This information can then be utilized to adapt medication treatments to an individual's genetic profile, which ultimately results in therapies that are more effective and safer.

Factors such as growing implementation of pharmacogenomics practice, growing elderly population, growing adoption of tailored therapy, rapidly increasing frequency of chronic ailments, and growing frequency of adversarial reactions are the key driving factors in the development of global pharmacogenomics market.

According to a study, the global pharmacogenomics market size was worth around USD 3.45 billion in 2023 and is expected to reach USD 8.36 billion by 2032., growing at a CAGR of around 10.33% during the forecast period.

U.S. will be the leading country in the North America region owing to growing execution of pharmacogenomics and quick implementation of latest healthcare technologies. 

The report also includes detailed profiles of key players such as Dynamic DNA Laboratories, Abbott Laboratories, Empire Genomics, LLC, Illumina, Inc., F. Hoffmann-La Roche Ltd., Myriad Genetics Inc., OneOme LLC, Thermo Fisher Scientific, Inc., and OPKO Health, Inc. among others.

Choose License Type

  • zion payment modes

RelatedNews

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

twitter

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

How it Works?

Our Company

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed